Levy Adam D.
SEC insider (Form 3/4/5 filer). CIK 0002061876. Chief Financial Officer at Acrivon Therapeutics, Inc. (ACRV). 6 reported Form 4/5 transactions since Sep 2024; latest on Aug 4, 2026. Located in WATERTOWN, MA.
Companies Levy Adam D. has filed insider reports for
- Acrivon Therapeutics, Inc. (ACRV): Officer, Chief Financial Officer
Levy Adam D.
CIK: 0002061876
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Acrivon Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Aug 4, 2026ACRV
Acrivon Therapeutics, Inc.
SaleDirect1.1K shares at avg. $1.57$2K - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
AwardDirect46.2K shares- - Mar 1, 2026ACRV
Acrivon Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
132.9K shares- - Jan 14, 2026ACRV
Acrivon Therapeutics, Inc.
PurchaseDirect8.8K shares at avg. $1.70$15K - Aug 1, 2025ACRV
Acrivon Therapeutics, Inc.
Tax PaymentDirect1.2K shares at avg. $1.26$1K - Apr 1, 2025ACRV
Acrivon Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
35.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 4, 2026 | ACRV Acrivon Therapeutics, Inc. | Sale | 1,142 | $1.57 | $1,793 | Direct |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc. | Award | 46,167 | - | $0 | Direct |
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc. | Award Stock Option (Right to Buy) | 132,925 | - | - | Direct |
| Jan 14, 2026 | ACRV Acrivon Therapeutics, Inc. | Purchase | 8,832 | $1.70 | $14,999 | Direct |
| Aug 1, 2025 | ACRV Acrivon Therapeutics, Inc. | Tax Payment | 1,164 | $1.26 | $1,467 | Direct |
| Apr 1, 2025 | ACRV Acrivon Therapeutics, Inc. | Award Stock Option (Right to Buy) | 35,209 | - | - | Direct |
1-6 of 6 transactions